Approval · Notice of Compliance 24624 · 2020
XEOMIN: Notice of Compliance 24624
Issued November 17, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 24624
- Date
- November 17, 2020
- Company
- Merz Pharmaceuticals GmbhFrankfurt, Hessen, Germany
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: for the treatment of chronic sialorrhea associated with neurological disorders in adults. new route of administration: intraglandular
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| XEOMIN | Not yet assigned | — |
Medicinal ingredients
- INCOBOTULINUMTOXINA 50 UNIT per VIAL
- INCOBOTULINUMTOXINA 100 UNIT per VIAL